.jpg)
AstraZeneca's $800M rare disease bet hits primary phase 3 goal, but competitive strength still unclear
A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps eneboparatide on track to come to market, but the lack of numbers in the readout leave questions about its positioning versus Ascendis Pharma’s Yorvipath unanswered.
A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps eneboparatide on track to come to market, but the lack of numbers in the readout leave questions about its positioning versus Ascendis Pharma’s Yorvipath unanswered.
